Tissue Engineering + Biofabrication Laboratory, Department of Health Sciences & Technology, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland.
Laboratory for Biointerfaces, Empa, Swiss Federal Laboratories for Materials Science and Technology, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland.
ACS Biomater Sci Eng. 2021 Jun 14;7(6):2198-2203. doi: 10.1021/acsbiomaterials.1c00298. Epub 2021 May 27.
Biomedical adhesives have been found to be an attractive alternative to suturing in several circumstances. However, to date most of the clinically approved formulations are based on synthetic and highly reactive toxic chemicals. In this work, we aimed to combine for the first time the bioactive properties of the cationic polysaccharide chitosan and its intrinsic electrostatic binding to negatively charged tissues with the biocompatible and clinically compliant enzymatic cross-linking scheme of fibrin glue. This synergistic activity led to the generation of a transglutaminase Factor XIII cross-linkable chitosan formulation with fast gelation kinetics, tunable mechanical properties, antibacterial activity, and strong adhesion to cartilage.
生物医学黏合剂在某些情况下已被证明是缝合的一种有吸引力的替代方法。然而,迄今为止,大多数临床批准的配方都是基于合成的和高度反应性的有毒化学物质。在这项工作中,我们首次旨在将阳离子多糖壳聚糖的生物活性特性及其与带负电荷的组织的固有静电结合与纤维蛋白胶的生物相容且临床兼容的酶交联方案结合起来。这种协同作用导致了具有快速胶凝动力学、可调节的机械性能、抗菌活性和对软骨强附着力的转谷氨酰胺酶因子 XIII 可交联壳聚糖制剂的产生。